Dataset Information


Ezrin Promotes Stem Cell Properties in Pancreatic Ductal Adenocarcinoma.

ABSTRACT: Self-renewal maintains the long-term clonogenic growth that is required for cancer relapse and progression, but the cellular processes regulating this property are not fully understood. In many diseases, self-renewal is enhanced in cancer stem cells (CSC), and in pancreatic ductal adenocarcinoma (PDAC), CSCs are characterized by the surface expression of CD44. In addition to cell adhesion, CD44 impacts cell shape and morphology by modulating the actin cytoskeleton via Ezrin, a member of the Ezrin/Radixin/Moesin (ERM) family of linker proteins. We examined the expression of Ezrin in PDAC cells and found higher levels of both total and activated Ezrin in CSCs compared with bulk tumor cells. We also found that the knockdown of Ezrin in PDAC cells decreased clonogenic growth, self-renewal, cell migration, and CSC frequency in vitro as well as tumor initiation in vivo. These effects were associated with cytoskeletal changes that are similar to those occurring during the differentiation of normal stem cells, and the inhibition of actin remodeling reversed the impact of Ezrin loss. Finally, targeting Ezrin using a small-molecule inhibitor limited the self-renewal of clinically derived low-passage PDAC xenografts. Our findings demonstrate that Ezrin modulates CSCs properties and may represent a novel target for the treatment of PDAC. IMPLICATIONS: Our findings demonstrate that Ezrin modulates CSCs' properties and may represent a novel target for the treatment of PDAC.


PROVIDER: S-EPMC6445733 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6411432 | BioStudies
2019-01-01 | S-EPMC6525821 | BioStudies
2017-01-01 | S-EPMC5503247 | BioStudies
2013-01-01 | S-EPMC3638599 | BioStudies
2017-01-01 | S-EPMC5540272 | BioStudies
2014-01-01 | S-EPMC4040703 | BioStudies
2015-01-01 | S-EPMC4494654 | BioStudies
2020-01-01 | S-EPMC7533489 | BioStudies
2015-01-01 | S-EPMC4537643 | BioStudies
2017-01-01 | S-EPMC5454033 | BioStudies